Celldex Therapeutics, Inc. (CLDX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
the bull case· 2
255
managers reporting a position in thirteen f filings
13fJun 30 '26+28.48%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 4
8 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized8 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '264
of the funds on file reporting a position in CLDX
n-portas of Jun 30 '260.70%
of State Street SPDR S and P Biotech ETF assets, largest weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Celldex Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2835, In Vitro & In Vivo Diagnostic Substances, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
High 39.75 at 4:00 am ET, low 37.62 at 1:00 pm ET.
Celldex Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · In Vitro & In Vivo Diagnostic Substances
CLDX (Celldex Therapeutics, Inc.) has 0 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
255 managers report a position worth $3.2B between them, and 35 of them hold 80% of it.